Stay updated on Pembrolizumab for Genomic Instability Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Genomic Instability Clinical Trial page.

Latest updates to the Pembrolizumab for Genomic Instability Clinical Trial page
- Check3 days agoChange DetectedRevision: v3.4.3 was added, replacing the previous Revision: v3.4.2.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedPage revision updated from v3.4.1 to v3.4.2. Core study details, eligibility criteria, and contact information appear unchanged.SummaryDifference0.1%

- Check31 days agoChange DetectedA minor revision update from v3.4.0 to v3.4.1 is shown; no other content changes are observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check39 days agoChange DetectedThe page now includes a Show glossary option and new QC metadata labels, including Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0, replacing the prior Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4.SummaryDifference0.2%

- Check53 days agoChange DetectedThe page revision updated from v3.3.3 to v3.3.4. No study data, eligibility criteria, or locations were modified. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check75 days agoChange DetectedAdded location sections for New Jersey and New York. Removed the separate 'New Jersey Locations' and 'New York Locations' blocks and updated the revision to v3.3.3.SummaryDifference0.3%

Stay in the know with updates to Pembrolizumab for Genomic Instability Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Genomic Instability Clinical Trial page.